A quasi-randomized clinical trial of oral tramadol versus low dose oxycodone for initial control of moderate cancer-related pain.

A quasi-randomized clinical trial of oral tramadol versus low dose oxycodone for initial control of moderate cancer-related pain. - A comparison of tramadol and oxycodone for cancer pain.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013665

Enrollment

Registered

2014-04-08

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasm

Interventions

Oral tramadol (100 - 300 mg/day) was given until the initial signs of significant analgesia were detected by patients Low dose oxycodone (10 - 40 mg/day) was given until the initial signs of significa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with moderate cancer-related pain (NRS 3 - 8 and STAS-J 2 - 3). Patients who agreed to participate in the study and signed informed consent form.

Exclusion criteria

Exclusion criteria: Patients with previously receiving opioid adminittration. Patients with severe cancer-related pain (NRS 9 - 10 and/or STAS-J 4).

Design outcomes

Primary

Measure	Time frame
Analgesic effects (NRS, STAS-J) Adverse effect rate	—

Secondary

Measure	Time frame
Efficacy rate	—

Countries

Japan

Contacts

Public ContactMotonao Kurahashi

Kansai Electric Power Hospital Department of Pharmacy

kurahashi.motonao@c3.kepco.co.jp06-6458-5821

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026